Cancers & treatments·Regimen libraryAdjuvant

TAC

Checked 2026-09-09

Adjuvant chemotherapy for node-positive early breast cancer

One cycle

every 21 days × 6 · about 18 weeks in total

21-day cycle × 6 (about 18 weeks)Intravenous

Components

Drug	Dose	Route	Days
Docetaxel Cytotoxic chemotherapy (taxane)	75 mg/m²	IV	D1
Doxorubicin Cytotoxic chemotherapy (anthracycline)	50 mg/m²	IV	D1
Cyclophosphamide Alkylating agent (oxazaphosphorine prodrug)	500 mg/m²	IV	D1

Cycles

21-day cycle

Emetogenicity

High (>90%)

G-CSF

Recommended

Notes

Febrile neutropenia in about a quarter of patients without G-CSF, so primary prophylaxis is standard.
Sequential AC then docetaxel (or dose-dense AC-T) is the more common alternative.

Used in

HR-positive / HER2-negative breast cancer HER2-positive breast cancer Triple-negative breast cancer (TNBC)

Products

DocetaxelDoxorubicinCyclophosphamide

Source

Martin (BCIRG 001), NEJM 2005: TAC versus FAC

Reference doses for a typical adult from the cited protocol or label. Doses are adjusted for renal and hepatic function, age, performance status and prior toxicity, and institutional protocols vary. Verify against the current label and your local protocol before treating. Not medical advice.